Loading...

We've got a brand new version of Simply Wall St! Try it out

Wayland Group

CNSX:WAYL
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WAYL
CNSX
CA$176M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Wayland Group Corp. produces and sells medical and non-medical cannabis for cannabis patients and consumers in Canada and internationally. The last earnings update was 248 days ago. More info.


Add to Portfolio Compare Print
  • Wayland Group has significant price volatility in the past 3 months.
WAYL Share Price and Events
7 Day Returns
0%
CNSX:WAYL
-4.3%
CA Pharmaceuticals
-0.7%
CA Market
1 Year Returns
-48.3%
CNSX:WAYL
-7.2%
CA Pharmaceuticals
-3.3%
CA Market
WAYL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Wayland Group (WAYL) 0% 0% 5.7% -48.3% - -
CA Pharmaceuticals -4.3% -15.5% -32.8% -7.2% 372.6% 361.1%
CA Market -0.7% -1.1% -2% -3.3% 6.2% 0.6%
1 Year Return vs Industry and Market
  • WAYL underperformed the Pharmaceuticals industry which returned -7.2% over the past year.
  • WAYL underperformed the Market in Canada which returned -3.3% over the past year.
Price Volatility
WAYL
Industry
5yr Volatility vs Market

Value

 Is Wayland Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Wayland Group. This is due to cash flow or dividend data being unavailable. The share price is CA$0.74.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Wayland Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Wayland Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:WAYL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.35
CNSX:WAYL Share Price ** CNSX (2019-05-06) in CAD CA$0.74
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 17.31x
Canada Market PE Ratio Median Figure of 541 Publicly-Listed Companies 14.4x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Wayland Group.

CNSX:WAYL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:WAYL Share Price ÷ EPS (both in CAD)

= 0.74 ÷ -0.35

-2.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wayland Group is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Wayland Group is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Wayland Group's expected growth come at a high price?
Raw Data
CNSX:WAYL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.07x
Canada Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Wayland Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Wayland Group's assets?
Raw Data
CNSX:WAYL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$0.89
CNSX:WAYL Share Price * CNSX (2019-05-06) in CAD CA$0.74
Canada Pharmaceuticals Industry PB Ratio Median Figure of 146 Publicly-Listed Pharmaceuticals Companies 2.2x
Canada Market PB Ratio Median Figure of 2,453 Publicly-Listed Companies 1.45x
CNSX:WAYL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:WAYL Share Price ÷ Book Value per Share (both in CAD)

= 0.74 ÷ 0.89

0.83x

* Primary Listing of Wayland Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wayland Group is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Wayland Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Wayland Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Wayland Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wayland Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
94.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Wayland Group expected to grow at an attractive rate?
  • Unable to compare Wayland Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Wayland Group's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Wayland Group's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:WAYL Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 94.3%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 57.7%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:WAYL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:WAYL Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:WAYL Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 3 -34 -43
2018-06-30 3 -31 -36
2018-03-31 3 -24 -12
2017-12-31 3 -20 -67
2017-09-30 4 -16 -63
2017-06-30 4 -12 -59
2017-03-31 4 -7 -74
2016-12-31 4 -5 -8
2016-09-30 4 -3 -4
2015-12-31 2 -2 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Wayland Group is high growth as no earnings estimate data is available.
  • Unable to determine if Wayland Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:WAYL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Wayland Group Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:WAYL Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:WAYL Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.35
2018-06-30 -0.36
2018-03-31 -0.14
2017-12-31 -0.97
2017-09-30 -1.20
2017-06-30 -1.26
2017-03-31 -1.91
2016-12-31 -0.22
2016-09-30 -0.11
2015-12-31 -0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Wayland Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of WAYL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Wayland Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Wayland Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Wayland Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Wayland Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Wayland Group performed over the past 5 years?

  • Wayland Group's last earnings update was 248 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Wayland Group's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Wayland Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Wayland Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Wayland Group's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Wayland Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Wayland Group Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:WAYL Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 2.68 -42.96 33.48
2018-06-30 3.18 -36.19 27.21
2018-03-31 2.68 -11.55 24.28
2017-12-31 3.22 -67.01 22.20
2017-09-30 3.83 -63.08 17.91
2017-06-30 4.00 -58.82 13.88
2017-03-31 4.25 -74.30 10.45
2016-12-31 4.06 -8.30 5.71
2016-09-30 3.72 -3.99 4.52
2015-12-31 1.97 -3.60 3.60
2014-12-31 0.00 -2.14 1.90
2013-12-31 -0.45 0.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Wayland Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Wayland Group has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Wayland Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Wayland Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Wayland Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Wayland Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Wayland Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Wayland Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Wayland Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Wayland Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Wayland Group Company Filings, last reported 10 months ago.

CNSX:WAYL Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 124.11 15.96 14.00
2018-06-30 98.48 16.92 8.25
2018-03-31 100.79 16.25 42.16
2017-12-31 61.52 24.15 24.57
2017-09-30 16.61 0.00 0.65
2017-06-30 20.69 0.00 7.98
2017-03-31 -59.33 64.13 16.50
2016-12-31 -3.24 25.19 16.19
2016-09-30 -2.32 7.97 0.00
2015-12-31 0.06 3.20 0.00
2014-12-31 3.42 2.75 0.04
2013-12-31
  • Wayland Group's level of debt (13.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Wayland Group's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Wayland Group has less than a year of cash runway based on current free cash flow.
  • Wayland Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 96.2% each year.
X
Financial health checks
We assess Wayland Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Wayland Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Wayland Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Wayland Group dividends.
If you bought CA$2,000 of Wayland Group shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Wayland Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Wayland Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:WAYL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 335 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:WAYL Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Wayland Group has not reported any payouts.
  • Unable to verify if Wayland Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Wayland Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Wayland Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Wayland Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Wayland Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Wayland Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Wayland Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ben Ward
COMPENSATION CA$2,824,890
AGE 39
CEO Bio

Mr. Benjamin Allan Ward, also known as Ben, serves as Chief Executive Officer of Maricann Group Inc. Mr. Ward served as Chief Financial Officer since August 4, 2017 at Maricann Group Inc. and also served as its President. Mr. Ward leads all facets of Maricann Group’s operations, including its strategic direction and execution, finance and industry relations. He is a Management Professional with significant experience in infrastructure development, business development and capital markets. He has an extensive experience in international development as the National Director of Economic Development for OMS International, with project implementation experience in over 40 countries. Mr. Ward served as the Chief Executive Officer and President of Canadian Cannabis Corp (Formerly Gold Party Payday Inc) from July 2013 to August 2016. Mr. Ward served as Chief Operating Officer of Sarissa Resources, Inc since September 2013. He served as President of Sarissa Resources, Inc. since September 2013. Mr. Ward served as the Chief Executive Officer and President of Enhanced Energy Solutions Corp. (alternative name Joshua Gold Resources Inc.) since June 28, 2011 until June 2013 and served as its Chief Financial Officer since December 23, 2010 until November 10, 2011. He served as the Treasurer of Joshua Gold Resources Inc. from December 23, 2010 to June 27, 2011. Mr. Ward has founded three public companies in the United States. He has been a Director of ABC Acquisition Corp. 1501 since June 4, 2010. He has been a Director of Sarissa Resources, Inc. since September 2013. Mr. Ward serves as a Director of Neue Energy Group, NexGen Energy and Niostar Corporation. He serves on the Advisory Board of Empower Global. He serves as a Director at Maricann Group Inc. April 20, 2017. Mr. Ward serves as a Director of Canadian Cannabis Corp (Formerly Gold Party Payday Inc). He served as a Director of Joshua Gold Resources Inc. since June 2010. He is an Executive Director of Kerr Street Community Services. He is responsible for management of 55 staff and 400 volunteers to deliver tangible relief programs relating primarily to food security and educational initiatives. Mr. Ward holds a (H) BA, Postgraduate Certificate of Management and a Master of Business Administration with a dual concentration of Finance and Operations from the Bradford University School of Management, England.

CEO Compensation
  • Insufficient data for Ben to compare compensation growth.
  • Ben's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Wayland Group management team in years:

1.7
Average Tenure
  • The average tenure for the Wayland Group management team is less than 2 years, this suggests a new team.
Management Team

Ben Ward

TITLE
CEO & Director
COMPENSATION
CA$3M
AGE
39

Scott Langille

TITLE
Chief Financial Officer
COMPENSATION
CA$303K
AGE
62
TENURE
1.8 yrs

Matthew McLeod

TITLE
President & Director
TENURE
0.3 yrs

James Hyssen

TITLE
Chief Operating Officer

Steven Bennett

TITLE
Chief Scientific Officer
TENURE
2.6 yrs

Shawn Alexander

TITLE
Vice President of Investor Relations

Graham Farrell

TITLE
Vice President of Communications

Geoff Kosar

TITLE
Vice President of Sales & Marketing
TENURE
1.5 yrs

Raymond Stone

TITLE
Secretary
Board of Directors Tenure

Average tenure of the Wayland Group board of directors in years:

1.1
Average Tenure
  • The average tenure for the Wayland Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Pathak

TITLE
Chairman of the Board
AGE
50
TENURE
1.5 yrs

Ben Ward

TITLE
CEO & Director
COMPENSATION
CA$3M
AGE
39
TENURE
2.3 yrs

Matthew McLeod

TITLE
President & Director
TENURE
0.1 yrs

Clay Horner

TITLE
Direcrtor
TENURE
0.8 yrs
Who owns this company?
Recent Open Market Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Wayland Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Wayland Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Investors Should Know About Wayland Group Corp.'s (CNSX:WAYL) Financial Strength

(CNSX:WAYL) is a small-cap stock with a market capitalization of CA$230m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Wayland Group Corp. (CNSX:WAYL) Investors Are Paying Above The Intrinsic Value

(CNSX:WAYL) from its intrinsic value? … by taking the expected future cash flows and discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

How Much Of Wayland Group (CNSX:WAYL) Do Insiders Own?

A look at the shareholders of Wayland Group (CNSX:WAYL) can tell us which group is most powerful. … Wayland Group is a smaller company with a market capitalization of CA$211m, so it may still be flying under the radar of many institutional investors. … See our latest analysis for Wayland Group

Simply Wall St -

Is Maricann Group Inc's (CNSX:WAYL) Balance Sheet A Threat To Its Future?

Investors are always looking for growth in small-cap stocks like Maricann Group Inc (CNSX:WAYL), with a market cap of CA$277m. … However, an important fact which most ignore is: how financially healthy is the business? … especially ones that are currently loss-making,

Simply Wall St -

Company Info

Description

Wayland Group Corp. produces and sells medical and non-medical cannabis for cannabis patients and consumers in Canada and internationally. It offers a range of CBD, balanced, and THC strains under the Kiwi, Northern Harvest, High Tide, Lost at Seed, Solara C, Rare Dankness, and Maricann names. The company was founded in 2013 and is headquartered in Oakville, Canada. Wayland Group Corp. is a subsidiary of Maricann Group Inc.

Details
Name: Wayland Group Corp.
WAYL
Exchange: CNSX
Founded: 2013
CA$175,572,769
237,260,499
Website: http://www.waylandgroup.com
Address: Wayland Group Corp.
2381 Bristol Circle,
Door D,
Oakville,
Ontario, L6H 5S9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX WAYL Common Shares Canadian National Stock Exchange CA CAD 24. Apr 2017
DB 75M Common Shares Deutsche Boerse AG DE EUR 24. Apr 2017
Number of employees
Current staff
Staff numbers
68
Wayland Group employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/03 00:41
End of day share price update: 2019/05/06 00:00
Last estimates confirmation: 2018/04/27
Last earnings filing: 2018/11/28
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.